Phase 4 N=146 Preventing Staphylococcal (Staph) Infection
Staphylococcal Infections
Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Abscess
Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants
N/A N=9,707 Nasopharyngeal Streptococcus Pneumoniae Carriage
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants
N/A N=987 Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children
Community-Acquired Staphylococcus Aureus
Primary: Medically Attended Skin and Soft Tissue Infections (MA-SSI) — 20.9; 17 percentage of partipants
N/A N=251 Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy
Infection · Pregnancy
Primary: Count of Participants With Positive Group B Streptococcus Rectovaginal Colonization Status at 35- 37 Weeks' Gestational Age — 20; 23 Participants — p=0.87
Phase 3 N=2,265 Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
Staphylococcal Infection
Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants
Phase 4 N=31 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score
N/A N=25 Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Fasciitis, Necrotizing · Severe Necrotizing Skin and Soft Tissue Infections · Fournier's Gangrene
Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants
Phase 2 N=1,310 Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Phase 4 N=110 S. Aureus Screening and Decolonization
Wound Infection Due to Staphylococcus Aureus · MRSA Infection of Postoperative Wound
Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants
N/A N=3,641 Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants
Phase 2 N=11 Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
Hematogenously Acquired Staphylococcus Aureus Osteomyelitis · Bone Infection · Osteomyelitis
Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence
N/A N=40 Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
Cellulitis
Primary: Visual Analog Scale(VAS) for Pain - Day 1 to 48 Hours — 79.64; 56.45; 39.71; 25.91 score on a scale
Phase 2 N=67 Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization
S. Aureus Oropharyngeal Colonization
Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants
Phase 2 N=122 Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
N/A N=60 Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
Phase 3 N=48 Intravenous Immunoglobulin for PANDAS
Obsessive-Compulsive Disorder · Children · Anxiety Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale Total Score — 20.59; 25.67 units on a scale — p=0.44
N/A N=110 Oral Probiotics Reduce Group B Streptococci Colonization in Pregnant Women
Group B Streptococcal Infection
Primary: Number of GBS-Positive Pregnant Women Who Became GBS-Negative at Childbirth — 21; 9 Participants
Phase 4 N=101 Skin and Soft Tissue Infection (SSTI) Study
Skin Diseases, Infectious · Soft Tissue Infections
Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71
Phase 3 N=813 Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Abscess · Wound Infection · Diabetic Foot
Primary: Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population — 88.6; 89.6 percentage of…
N/A N=139 Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
N/A N=80 Skin Prep to Reduce Postoperative Shoulder Infection
Shoulder Infection
Primary: Skin Swab and Culture With Colony Forming Units (CFUs) — 39; 51; 35; 22 negative skin cultures — p=0.68
Phase 3 N=199 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
Methicillin-Resistant Staphylococcus Aureus · Bacterial Infections · Staphylococcal Skin Infections
Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants
Phase 2 N=667 Prevention of GBS Colonization Via Immunity
Beta Haemolytic Streptococcal Infection
Primary: The Time to First Vaginal Swab That is Type III GBS Culture Positive, With All Previous Cultures Negative for Type III GBS, Not Just the Immediately Preceding Culture…
Phase 4 N=1,291 Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Scabies · Yaws · Impetigo
Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo
Phase 4 N=50 Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess
Cutaneous Abscess
Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants
N/A N=32 Microcurrent Dressing to Treat Infections, Before, During and After Surgery
Shoulder Arthropathy Associated With Other Conditions · Shoulder Arthritis · Shoulder Osteoarthritis
Primary: Measurement of Change in Cutibacterium Acnes — 3; 8; 3; 2 Participants — p=0.004
N/A N=38 Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
Musculoskeletal Infection · Acute Hematogenous Osteomyelitis · Septic Arthritis
Primary: Number of Participants With a Pathogen Identified by the Initial Karius Test (IP1) and Standard Culture Methods — 23; 26; 15 Participants
Phase 2 N=44 Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
Bone and Joint Infection
Primary: Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated — 0; 0 participants
Phase 2 N=172 Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
Streptococcal Infection · Gram-positive Bacterial Infection · Bacterial Infection
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in Mothers and Infants at Delivery/Birth — 5.39; 0.41; 4.37; 0.4 µg/mL